PRNB News and Press, Principia Biopharma Inc. From 01/09/20

Company expands focus on immune-mediated diseases and  suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company foc...

Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...

Company’s lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical compan...

Principia Biopharma ( PRNB -3.2% ) now expects final data from its Phase 3 clinical trial evaluating lead candidate PRN1008 in pemphigus patients in H2 2021 instead of H1 2022. More news on: Principia Biopharma Inc., Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immune-mediated diseases, today announced up...

Gainers:  Technical Communications (NASDAQ: TCCO ) +323% . More news on: Technical Communications Corporation, Venus Concept Inc., Iterum Therapeutics plc, Stocks on the move, Read more ...

Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...

ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced consistent positive data from an ongoing Phase 1/2 trial of its investigationa...

Principia Biopharma (PRNB) is a San Francisco-based clinical-stage biotechnology company. The company is focused on the development of Bruton's tyrosine kinase ((BTK)) inhibitors as a potential treatment for rare autoimmune disorders. Source: Principia Biopharma corporate presentation ...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the Stifel Healthcare Confer...